In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Subscribe To Our Newsletter & Stay Updated
